Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.


Sunitinib (sunitinib malate; SU11248; SUTENT) is a novel multi-targeted receptor tyrosine kinase inhibitor currently approved for the treatment of metastatic renal cell carcinoma. To analyze the possible use of this compound in combination with immunotherapeutic approaches, we investigated the effects of sunitinib on the human peripheral T cells and the… (More)
DOI: 10.1016/j.clim.2009.11.013


7 Figures and Tables